Engagement of CD14 mediates the inflammatory potential of monosodium urate crystals

Peter Scott1, Hong Ma, Suganya Viriyakosol

  • 1Veterans Affairs Medical Center, Department of Medicine, University of California-San Diego, San Diego, CA 92161, USA.

Insights

CD14 engagement is key in monosodium urate (MSU) crystal-induced gouty inflammation. Blocking CD14 significantly reduces IL-1beta release and leukocyte influx, highlighting its central role in the inflammatory response.

Area of Science:

  • Immunology
  • Inflammation Research
  • Crystal-Induced Arthritis

Background:

  • Phagocyte ingestion of monosodium urate (MSU) crystals triggers gouty inflammation.
  • Macrophage activation involves TLR2/TLR4, caspase-1, and the NLRP3 inflammasome.
  • CD14 is a pattern recognition receptor interacting with TLR2 and TLR4.

Purpose of the Study:

  • To investigate the role of CD14 in MSU crystal-induced gouty inflammation.
  • To determine if CD14 influences MSU crystal recognition, phagocytosis, and subsequent inflammatory signaling.

Main Methods:

  • In vitro binding assays with soluble CD14 (sCD14) and MSU crystals.
  • Macrophage phagocytosis assays using CD14(-/-) bone marrow-derived macrophages (BMDMs).
  • Analysis of inflammatory mediator release (IL-1beta, CXCL1) and inflammasome activation in BMDMs.
  • In vivo studies using CD14(-/-) mouse air pouches to assess leukocyte influx and IL-1beta induction.

Main Results:

  • MSU crystals directly bound sCD14 in vitro.
  • CD14(-/-) BMDMs showed reduced IL-1beta and CXCL1 release, with impaired caspase-1 activation and NLRP3 inflammasome activity.
  • sCD14 coating restored MSU crystal-induced inflammatory mediator production in CD14(-/-) BMDMs.
  • In vivo, CD14(-/-) mice exhibited significantly reduced leukocyte influx and IL-1beta induction in response to MSU crystals.

Conclusions:

  • CD14 engagement is a critical determinant of MSU crystal's inflammatory potential.
  • CD14 influences MSU crystal recognition and subsequent pro-inflammatory cytokine production.
  • Targeting CD14 may offer a therapeutic strategy for gouty inflammation.